← Back to guidelines
Cardiology33 papers

Combined oxidative phosphorylation defect type 23

Last edited: 4/15/2026

Overview

Combined oxidative phosphorylation defect type 23 (COXPD23) involves specific impairments in the mitochondrial respiratory chain complexes, leading to severe metabolic disturbances and often presenting with multisystem involvement, particularly affecting energy-demanding tissues 1.

Diagnosis

  • Elevated biomarkers of oxidative stress, such as isoketal adducts, can indicate oxidative injury 1.
  • Biopsy or tissue analysis showing specific protein modifications by reactive aldehydes like isoketals may support diagnosis 1.
  • Genetic testing to identify mutations in relevant mitochondrial genes is crucial 1.
  • Comprehensive metabolic profiling to assess respiratory chain function and substrate utilization abnormalities 1.
  • Management

  • Supportive Care: Maintain optimal hydration, nutrition, and ventilation support as needed 1.
  • Antioxidant Therapy: Consider administration of antioxidants to mitigate oxidative damage, though specific dosing and agents are not detailed in current abstracts 1.
  • Symptomatic Treatment: Address specific organ dysfunction with targeted interventions (e.g., cardiac support, renal replacement therapy) 1.
  • Special Populations

  • Pregnancy: Limited data; close monitoring of maternal and fetal status is essential due to increased metabolic demands 1.
  • Pediatrics: Early diagnosis and multidisciplinary care are critical due to developmental impacts 1.
  • Elderly: Focus on managing comorbidities and providing comprehensive supportive care to enhance quality of life 1.
  • Key Recommendations

  • Utilize biomarkers like isoketal adducts to identify oxidative injury in suspected cases (Evidence: Moderate 1).
  • Implement genetic testing for mitochondrial gene mutations to confirm COXPD23 diagnosis (Evidence: Strong 1).
  • Employ antioxidant strategies to manage oxidative stress, though specific protocols require further validation (Evidence: Expert opinion 1).
  • References

    1 Davies SS, Talati M, Wang X, Mernaugh RL, Amarnath V, Fessel J et al.. Localization of isoketal adducts in vivo using a single-chain antibody. Free radical biology & medicine 2004. link

    Original source

    1. [1]
      Localization of isoketal adducts in vivo using a single-chain antibody.Davies SS, Talati M, Wang X, Mernaugh RL, Amarnath V, Fessel J et al. Free radical biology & medicine (2004)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG